China invest $65million in umbilical cord blood that is rich in stem cells

Kohlberg Kravis Roberts & Co. L.P. will invest $65 million into China Cord BloodCorp, the country’s largest operator of services for umbilical cord blood that is rich in stem cells, to capitalize on China’s fast-growing health-care services industry.
Listed on the New York Stock Exchange since 2009, CCBC was the first licensed cord-blood banking operator in China, providing collection, testing, processing and storage services. CCBC runs the largest cord-blood banking network in China in terms of geographical coverage, with exclusive licenses to service Beijing, Guangdong Province and Zhejiang Province. This area covers more than 180 million people and has 1.9 million new births annually.
Cord blood contains large quantities of stem cells that, if stored properly, can later be used to treat life-threatening diseases. The applications of cord-blood stem cells are expanding, and can be used to treat more than 80 types of diseases, such as leukemia, lymphoma, and inherited immune system disorders.